The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Incretin-Based Drugs Market Evolve From 2026 To 2030?
The incretin-based drugs market size has experienced robust growth in recent years. It is projected to expand from $27.83 billion in 2025 to $29.88 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. Historically, this growth can be attributed to the prevalence of type 2 diabetes, insulin resistance rates, lifestyle-related metabolic disorders, the adoption of endocrinology drugs, and various hospital diabetes programs.
The incretin-based drugs market size is projected to experience robust expansion over the coming years. Its value is anticipated to reach $39.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period stems from factors such as the worldwide obesity epidemic, the increasing need for weight management medications, advancements in long-acting incretin therapies, customized diabetes treatment, and a greater emphasis on preventive metabolic health. Key trends anticipated in this period encompass the swift uptake of GLP-1 receptor agonists, the broadening of indications for obesity management, a rise in the application of oral incretin therapies, the development of more combination therapy strategies, and enhanced patient compliance due to weekly dosing.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp
What Drivers Are Influencing The Incretin-Based Drugs Market?
The increasing occurrence of type 2 diabetes mellitus is anticipated to drive the expansion of the incretin-based drugs market in the future. Type 2 diabetes mellitus, a long-term metabolic condition, is marked by resistance to insulin and reduced insulin secretion, resulting in high blood glucose levels. This condition’s rise is linked to unhealthy eating habits and lack of physical activity, which lead to insulin resistance and hinder the body’s ability to manage blood sugar. Incretin-based drugs address type 2 diabetes by stimulating insulin release post-meal and decreasing glucagon production, thereby assisting in lowering blood sugar. These drugs also slow gastric emptying and suppress hunger, contributing to better glucose management and weight reduction. A relevant example shows that in June 2024, the National Health Service, a UK government body, reported that approximately 549,000 additional individuals in England were at risk of developing type 2 diabetes in 2023, elevating the total pre-diabetes population to over 3.6 million, marking a nearly 20% surge from 2022. Consequently, the growing prevalence of type 2 diabetes mellitus is fueling the growth of the incretin-based drugs market.
Which Segment Areas Are Covered In The Incretin-Based Drugs Market Analysis?
The incretin-based drugs market covered in this report is segmented –
1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Type 2 Diabetes, Obesity, Other Applications
Subsegments:
1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
What Key Developments And Trends Are Impacting The Incretin-Based Drugs Market?
Major companies within the incretin-based drugs market are concentrating on developing generic drug alternatives to provide more effective and patient-friendly treatment options for type 2 diabetes. A generic medication shares the same active ingredients, strength, dosage form, and administration route as a brand-name drug but is marketed under its chemical name without brand labeling. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product received approval from the Food and Drug Administration (FDA). It is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a new, more affordable alternative amidst ongoing shortages of GLP-1 medications.
Which Global Companies Are Actively Competing In The Incretin-Based Drugs Market?
Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation
Read the full incretin-based drugs market report here:
https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Incretin-Based Drugs Market?
North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Incretin-Based Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp
Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Drug Formulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report
Pharmaceuticals Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model